EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis

Yan Zhao, Litao Zhang, Liming Wu, Bin Yang iD, Jinyan Wang, Yumei Li iD, Qingchun Diao, Jingyi Li, Qing Sun iD, Xiaohong Zhu, Xiaoyong Man iD, Lihua Wang iD und 15 weitere

International Journal of Dermatology · 2025

DOI: 10.1111/ijd.70175 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Yan Zhao und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Interleukin-4 Receptor alpha Subunit, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Keymed Biosciences (Chengdu) Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elderly patients with moderate‐to‐severe atopic dermatitis (AD) often exhibit more heterogeneous inflammatory profiles compared with younger adults. To evaluate the efficacy and safety of stapokibart, an anti‐interleukin‐4 receptor α subunit (IL‐4Rα) monoclonal antibody, in different age subgroups.

Methods

Eligible adults were randomized to receive subcutaneous stapokibart 300 mg every 2 weeks (Q2W; loading dose 600 mg) or placebo for 16 weeks. All patients subsequently received stapokibart 300 mg Q2W for 36 weeks. In this post hoc analysis, patients were classified as elderly (aged ≥ 60 years, n = 93) and non‐elderly patients (aged 18 and < 60 years, n = 407). Main efficacy outcomes included ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI‐75), Investigator's Global Assessment (IGA) 0/1, and ≥ 4‐point reduction in weekly average of daily peak pruritus Numerical Rating Scale (PP‐NRS) score.

Results

In elderly patients at Week 16, response rates for stapokibart versus placebo were 56.0% vs. 14.0% for EASI‐75 ( p < 0.0001), 40.0% vs. 7.0% for IGA 0/1 ( p = 0.0003), and 32.0% vs. 7.0% for ≥ 4‐point reduction in weekly average of daily PP‐NRS ( p = 0.0023). In non‐elderly patients, corresponding response rates were 69.7% vs. 28.3%, 45.3% vs. 18.0%, and 36.8% vs. 12.7%, respectively (all p < 0.0001). Within both age subgroups, progressive improvements across all efficacy measures were observed during the maintenance treatment period. The incidence of treatment‐emergent adverse events was similar between stapokibart and placebo groups during the 16‐week treatment period, regardless of age.

Conclusion

Stapokibart was effective and had a favorable safety profile in elderly patients with moderate‐to‐severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicInterleukin-4 Receptor alpha SubunitAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalHumansMaleFemaleMiddle AgedAgedSeverity of Illness IndexAdultTreatment OutcomeAge FactorsDouble-Blind MethodYoung AdultAdolescentPruritusAged, 80 and overInjections, Subcutaneous

Stichwörter der Autor:innen

elderly patientsmoderate‐to‐severe atopic dermatitisstapokibart

Substanzen

Interleukin-4 Receptor alpha SubunitAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalIL4R protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Peking University People's Hospital, Beijing, China.
  • Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
  • Department of Dermatology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
  • Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Dermatology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
  • Department of Dermatology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

ORCID-Profile: Bin Yang, Yumei Li, Qing Sun, Xiaoyong Man, Lihua Wang, Linfeng Li, Fuqiu Li, Jianzhong Zhang

Förderung

  • Keymed Biosciences (Chengdu) Co., Ltd

Zitieren

APA

Zhao, Y., Zhang, L., Wu, L., Yang, B., Wang, J., Li, Y., Diao, Q., Li, J., Sun, Q., Zhu, X., Man, X., Wang, L., Feng, Y., Cai, T., Zeng, H., Li, L., Lu, J., Ren, H., Li, F., …, & Zhang, J. (2025). Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis. International Journal of Dermatology. https://doi.org/10.1111/ijd.70175

Vancouver

Zhao Y, Zhang L, Wu L, Yang B, Wang J, Li Y, et al. Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis. International Journal of Dermatology. 2025. doi:10.1111/ijd.70175

BibTeX
@article{Zhao2025,
  author = {Zhao, Yan and Zhang, Litao and Wu, Liming and Yang, Bin and Wang, Jinyan and Li, Yumei and Diao, Qingchun and Li, Jingyi and Sun, Qing and Zhu, Xiaohong and Man, Xiaoyong and Wang, Lihua and Feng, Yanyan and Cai, Tao and Zeng, Huiming and Li, Linfeng and Lu, Jianyun and Ren, Hong and Li, Fuqiu and Lu, Qianjin and Tao, Xiaohua and Xiao, Rong and Ji, Chao and Sun, Jing and Qiu, Yanping and Chen, Bo and Zhang, Jianzhong},
  title = {Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis},
  journal = {International Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ijd.70175}
}
Kostenlos starten →